Skip to content

EV / sales at other companies

Opko Health logo
Opko HealthOPK
1.6×-0.1×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
3.7×-6.9×
AMP
Amphastar PharmaceuticalsAMPH
1.9×-0.6×
Theravance Biopharma logo
Theravance BiopharmaTBPH
5.4×-0.5×
HRO
HarrowHROW
5.7×-0.6×
Precigen logo
PrecigenPGEN
102.1×

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+13.4%
Enterprise value$831.61M+12.7%
P/S4.1×-5.0×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s EV / sales?
Phathom Pharmaceuticals, Inc. (PHAT) reported EV / sales of 4.2× in Q1 2026.
How has Phathom Pharmaceuticals, Inc.'s EV / sales changed year-over-year?
Phathom Pharmaceuticals, Inc.'s EV / sales decreased by 19.6% year-over-year, from 5.2× to 4.2×.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s EV / sales?
Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s EV / sales has grown at a -86.8% compound annual growth rate (CAGR), from 411.6× to 7.2×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.